These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8227490)

  • 81. Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study.
    Savoldi F; Somenzini G; Ecari U
    Curr Med Res Opin; 1990; 12(3):185-90. PubMed ID: 2272192
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.
    Marchesi C; Ampollini P; Signifredi R; Maggini C
    Neuropsychobiology; 1997; 36(1):25-31. PubMed ID: 9211441
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder.
    O'Sullivan GH; Noshirvani H; Başoğlu M; Marks IM; Swinson R; Kuch K; Kirby M
    Br J Psychiatry; 1994 Jul; 165(1):79-86. PubMed ID: 7802851
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Interactive model of therapeutic response in panic disorder: moclobemide, a case in point.
    Uhlenhuth EH; Warner TD; Matuzas W
    J Clin Psychopharmacol; 2002 Jun; 22(3):275-84. PubMed ID: 12006898
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Double-blind acute clonazepam vs. placebo in carbon dioxide-induced panic attacks.
    Nardi AE; Valença AM; Nascimento I; Mezzasalma MA; Zin WA
    Psychiatry Res; 2000 May; 94(2):179-84. PubMed ID: 10808043
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine.
    den Boer JA; Westenberg HG; Kamerbeek WD; Verhoeven WM; Kahn RS
    Int Clin Psychopharmacol; 1987 Jan; 2(1):21-32. PubMed ID: 3117876
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Milnacipran in panic disorder with agoraphobia and major depressive disorder: a case report.
    Chen MH; Liou YJ
    Clin Neuropharmacol; 2011; 34(5):201-2. PubMed ID: 21926486
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients.
    van Megen HJ; Westenberg HG; den Boer JA
    Biol Psychiatry; 1996 Oct; 40(8):804-6. PubMed ID: 8894076
    [No Abstract]   [Full Text] [Related]  

  • 89. The efficacy of milnacipran in panic disorder: an open trial.
    Blaya C; Seganfredo AC; Dornelles M; Torres M; Paludo A; Heldt E; Manfro GG
    Int Clin Psychopharmacol; 2007 May; 22(3):153-8. PubMed ID: 17414741
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Sertraline treatment of panic disorder: results of a long-term study.
    Rapaport MH; Wolkow R; Rubin A; Hackett E; Pollack M; Ota KY
    Acta Psychiatr Scand; 2001 Oct; 104(4):289-98. PubMed ID: 11722304
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Controlled trials of inositol in psychiatry.
    Levine J
    Eur Neuropsychopharmacol; 1997 May; 7(2):147-55. PubMed ID: 9169302
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin.
    Den Boer JA; Westenberg HG
    Psychopharmacology (Berl); 1990; 102(1):85-94. PubMed ID: 1697419
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial.
    Fahy TJ; O'Rourke D; Brophy J; Schazmann W; Sciascia S
    J Affect Disord; 1992 May; 25(1):63-75. PubMed ID: 1624646
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up.
    de Beurs E; van Balkom AJ; Van Dyck R; Lange A
    Acta Psychiatr Scand; 1999 Jan; 99(1):59-67. PubMed ID: 10066008
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Sex differences in clinical presentation and response in panic disorder: pooled data from sertraline treatment studies.
    Clayton AH; Stewart RS; Fayyad R; Clary CM
    Arch Womens Ment Health; 2006 May; 9(3):151-7. PubMed ID: 16292466
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Epinephrine infusions in panic disorder: a double-blind placebo-controlled study.
    Veltman DJ; van Zijderveld GA; van Dyck R
    J Affect Disord; 1996 Jul; 39(2):133-40. PubMed ID: 8827423
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.
    Pande AC; Greiner M; Adams JB; Lydiard RB; Pierce MW
    Biol Psychiatry; 1999 Sep; 46(6):860-2. PubMed ID: 10494457
    [TBL] [Abstract][Full Text] [Related]  

  • 98. MDMA (Ecstasy) precipitation of panic disorder.
    Pallanti S; Mazzi D
    Biol Psychiatry; 1992 Jul; 32(1):91-5. PubMed ID: 1356491
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome.
    Perna G; Bertani A; Caldirola D; Gabriele A; Cocchi S; Bellodi L
    J Clin Psychopharmacol; 2002 Jun; 22(3):300-8. PubMed ID: 12006901
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder.
    Black DW; Gabel J; Hansen J; Schlosser S
    Ann Clin Psychiatry; 2000 Dec; 12(4):205-11. PubMed ID: 11140921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.